

## Special Issue

# Modulation of Anti-Tumor Immunity and Tumor Microenvironment

### Message from the Guest Editor

In cancer treatment, immunotherapy has demonstrated promising clinical efficacy for the improvement of survival and quality of life. In clinical practice of cancer therapy, the combination of various treatment modalities remains an important strategy, such as the application of immunotherapy, chemotherapy, target therapy, hyperthermia and radiotherapy, etc. Therefore, research on the modulation of anti-tumor and tumor microenvironments using various therapeutic modalities is important for further augmentation of cancer treatment outcomes.

For this Special Issue, we invite you to contribute original research articles or reviews on all aspects related to the theme of "Modulation of Anti-Tumor Immunity and Tumor Microenvironment". All research regarding basic, translational and clinical studies as well as development of new therapeutic agents or drug repositioning is welcome. Relevant topics include, but are not limited to, the following:

- Anti-tumor immunity;
- Tumor microenvironment;
- Immunotherapy;
- Chemotherapy;
- Target therapy;
- Hyperthermia;
- Radiotherapy;
- Novel therapeutic agents

---

### Guest Editor

Dr. Yu-Jen Chen

1. Chief, Department of Biotechnology Medicine, MacKay Memorial Hospital, Taipei, Taiwan
2. Senior Attending Physician, Department of Radiation Oncology, MacKay Memorial Hospital, Taipei, Taiwan
3. Director, Laboratory of Cancer Therapeutics, MacKay Memorial Hospital, Taipei, Taiwan
4. Professor, Department of Artificial Intelligence and Medical Application, MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan
5. Professor, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

---

**Deadline for manuscript submissions**



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/187897](https://mdpi.com/si/187897)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).